BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-3167 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-3167\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07489482-489@assetmemo.bio
DTSTAMP:20261121T005813Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-3167: Phase 1 readout est. (NCT07489482)
DESCRIPTION:SHR-3167\, phase 1.\nStudy: A Clinical Study Comparing the Rela
 tive Bioavailability and Safety of SHR-3167 Injection\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/shr-3167#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07489482
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472725-489@assetmemo.bio
DTSTAMP:20261121T005813Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-3167: Phase 2 readout est. (NCT07472725)
DESCRIPTION:SHR-3167\, phase 2\, Type 2 Diabetes.\nStudy: A Study Comparing
  Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-D
 ose Titration in Adults With Type 2 Diabetes Inadequately Controlled With 
 Oral Antihyperglycemic Agents\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07472725
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07032688-489@assetmemo.bio
DTSTAMP:20261121T005813Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:SHR-3167: Phase 1 readout est. (NCT07032688)
DESCRIPTION:SHR-3167\, phase 1\, Type 2 Diabetes.\nStudy: A Clinical Study 
 to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-
 3167 in Subjects With Type 2 Diabetes\nEstimated primary completion: March
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07032688
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07920939-489@assetmemo.bio
DTSTAMP:20261121T005813Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:SHR-3167: Phase 3 readout est. (NCT07920939)
DESCRIPTION:SHR-3167\, phase 3\, Type 2 Diabetes.\nStudy: Efficacy and Safe
 ty of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Ad
 ults With Insulin-Naive Type 2 Diabetes\nEstimated primary completion: Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07920
 939
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913061-489@assetmemo.bio
DTSTAMP:20261121T005813Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:SHR-3167: Phase 3 readout est. (NCT07913061)
DESCRIPTION:SHR-3167\, phase 3\, Type 2 Diabetes.\nStudy: A Study Comparing
  SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently T
 reated With Basal Insulin\nEstimated primary completion: January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07913061
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
